Procurement and Installation of Mass Spectrometer

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

CDER-2026-131687

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

SBA

Place of Performance

Saint Louis, Missouri, UNITED STATES

SourceSAM
Documents1
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Sources Sought notice for the procurement and installation of a high-resolution mass spectrometry system with integrated ultra-high-performance liquid chromatography (UHPLC) capability. This acquisition is intended to enhance the FDA’s analytical capacity for the evaluation of pharmaceutical drug substances and products, with a particular focus on the detection and characterization of nitrosamine impurities, small molecules, peptides, and other biomolecules. The place of performance for this requirement is Saint Louis, Missouri. The referenced brand-name product for this procurement is the Thermo Scientific Orbitrap Excedion Pro BioPharma MS and UHPLC system. However, the Government is conducting this procurement on a brand-name-or-equal basis, meaning that vendors may propose equivalent systems, provided they meet or exceed the specified salient characteristics. The procurement falls under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6640. The scope of this requirement encompasses the delivery, installation, and qualification (IQ/OQ) of a fully integrated LC-MS system, as well as vendor-provided instrument familiarization and operational training. The system must be capable of supporting regulatory-grade analytical workflows for pharmaceutical quality evaluation and impurity characterization. Key technical requirements include: - High-resolution, accurate-mass (HRAM) mass spectrometry for resolving complex mixtures and trace-level impurities in pharmaceutical samples. - A mass analyzer with sufficient resolving power for high-confidence molecular identification and impurity characterization. - Extended mass range capability, with a minimum range up to m/z 12,000, to accommodate both small molecules and larger biomolecules. - Sensitivity adequate for trace-level detection of pharmaceutical impurities, including nitrosamines. - Compatibility with an integrated UHPLC system suitable for biocompatible analytical applications. - Integrated instrument control and data analysis software supporting advanced workflows for small molecule and peptide characterization. - Automated data processing, spectral deconvolution, and identification workflows for complex pharmaceutical samples. - Centralized data management capabilities to ensure secure instrument operation, workflow automation, and laboratory data integration. Offerors proposing an “equal” product must provide clear and detailed documentation demonstrating how their system meets or exceeds each of these salient characteristics. The Government will evaluate all quotations based on their ability to fulfill these requirements. This procurement is set aside for SBA-eligible entities. Interested parties should note that the contracting entity is the FDA Office of Acquisition and Grant Services. The primary point of contact for this opportunity is Reagan Davis, who can be reached at [email protected] or 301-796-0910. The notice was posted on January 4, 2026, and responses are due by June 4, 2026. The opportunity is currently active and further details, including any attachments, can be accessed via the official SAM.gov listing at https://sam.gov/opp/4721382ea1564118b00c638baa5fad79/view. Contractors with expertise in analytical laboratory instrument manufacturing and the ability to deliver, install, and qualify high-performance LC-MS systems that meet the FDA’s stringent requirements are encouraged to review the full notice and consider responding.